RecruitingPhase 2NCT01624805

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Studying Aplastic Anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Tapan M Kadia, M.D
M.D. Anderson Cancer Center
Intervention
Anti-Thymocyte Globulin(biological)
Enrollment
140 enrolled
Eligibility
18 years · All sexes
Timeline
20122026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01624805 on ClinicalTrials.gov

Other trials for Aplastic Anemia

Additional recruiting or active studies for the same condition.

See all trials for Aplastic Anemia

← Back to all trials